Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease.
NCT07339514 is registered in ClinicalTrials.gov with ExoRNA Bioscience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study of ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease.
- Lead sponsor
- ExoRNA Bioscience
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- February 11, 2025
- Completion date
- May 30, 2026
- Enrollment
- 27 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.